We claim:

1. A method for the treatment of behavioral and psychological symptoms in a patient with dementia comprising administering to the patient an effective dose of masupirdine, or a pharmaceutically acceptable salt thereof, wherein the effective dose of masupirdine or a pharmaceutically acceptable salt thereof is selected from 25 mg to 125 mg.

2. The method of claim 1, wherein the treatment comprises administering to the patient 25 mg to 50 mg of masupirdine, or a pharmaceutically acceptable salt thereof.

3. The method of claim 1, wherein the treatment comprises administering to the patient 50 mg to 100 mg of masupirdine, or a pharmaceutically acceptable salt thereof.

4. The method of claim 1, wherein the treatment comprises administering to the patient 25 mg, 50 mg, 75 mg, 100 mg or 125 mg of masupirdine, or a pharmaceutically acceptable salt thereof.

5. The method of claims 1 to 4, wherein the pharmaceutically acceptable salt of masupirdine is dimesylate monohydrate.

6. A method for the treatment of behavioral and psychological symptoms in a patient with dementia comprising administering to the patient an effective dose of masupirdine dimesylate monohydrate, wherein the effective dose of masupirdine dimesylate monohydrate is selected from 25 mg to 125 mg.

7. The method of claim 6, wherein the treatment comprises administering to the patient 25 mg, 50 mg, 75 mg, 100 mg or 125 mg of masupirdine dimesylate monohydrate.

8. A method for the treatment of behavioral and psychological symptoms in a patient with dementia comprising administering to the patient an effective dose of masupirdine, or a pharmaceutically acceptable salt thereof in combination

with donepezil or a pharmaceutically acceptable salt thereof and memantine or a pharmaceutically acceptable salt thereof.

9. The method of claim 1, 6 or 8, wherein the behavioral and psychological symptoms in patient with dementia are selected from agitation/aggression, delusions and/or hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, euphoria/elation, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, and appetite and eating change.

10. The method of claim 1, 6, 8 or 9, wherein the dementia is selected from Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, Lewy body dementia, vascular dementia, and frontotemporal dementia.

11. The method of claim 1, 6 or 8, wherein the dementia is Alzheimer's disease dementia and the behavioral and psychological symptoms in patient with Alzheimer's disease dementia are selected from agitation/aggression, delusions and/or hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, euphoria/elation, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, and appetite and eating change.

12. The method of claim 1, 6 or 8, wherein the dementia is Parkinson's disease dementia and the behavioral and psychological symptoms in patient with Parkinson's disease dementia are selected from agitation/aggression, delusions and/or hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, euphoria/elation, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, and appetite and eating change.

13. The method of claim 1, 6 or 8, wherein the behavioral and psychological symptom in patient with dementia is agitation/aggression in dementia.

14. The method of claim 1, 6 or 8, wherein the behavioral and psychological symptom in patient with dementia is agitation/aggression in Alzheimer's disease dementia.

15. The method of claim 13 or 14, wherein the patient has a baseline score of 1 or greater in the agitation/aggression subscale of the NPI-12.

16. The method of claim 1, 6 or 8, wherein the behavioral and psychological symptom in patient with dementia is delusions and/or hallucinations in dementia.

17. The method of claim 1, 6 or 8, wherein the behavioral and psychological symptom in patient with dementia is delusions and/or hallucinations in Alzheimer's disease dementia.

18. The method of claim 16 or 17, wherein the patient has a baseline score of 1 or greater in the delusions and/or hallucinations subscale of the NPI-12.

19. The method of claims 16 to 18, wherein the cognitive deficit is treated in patients with delusions and/or hallucinations.

20. A pharmaceutical composition, comprising an effective dose of masupirdine or a pharmaceutically acceptable salt thereof as claimed in claims 1 to 4, for the treatment of behavioral and psychological symptoms in a patient with dementia.

21. A pharmaceutical composition, comprising an effective dose of masupirdine or a pharmaceutically acceptable salt thereof, donepezil or a pharmaceutically acceptable salt thereof and memantine or a pharmaceutically acceptable salt thereof as claimed in claim 8, for the treatment of behavioral and psychological symptoms in a patient with dementia.

22. The pharmaceutical composition of claim 20 or 21, wherein the behavioral and psychological symptoms in patient with dementia are selected from agitation/aggression, delusions and/or hallucinations, aberrant motor behavior,

aberrant vocalizations, anxiety, euphoria/elation, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, and appetite and eating change.

23. The pharmaceutical composition of claims 20 to 22, wherein the dementia is selected from Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, Lewy body dementia, vascular dementia, and frontotemporal dementia.

24. The pharmaceutical composition of claim 20 or 21, wherein the dementia is Alzheimer's disease dementia and the behavioral and psychological symptoms in patient with Alzheimer's disease dementia are selected from agitation/aggression, delusions and/or hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, euphoria/elation, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, and appetite and eating change.

25. The pharmaceutical composition of claim 20 or 21, wherein the dementia is Parkinson's disease dementia, and the behavioral and psychological symptoms in patient with Parkinson's disease dementia are selected from agitation/aggression, delusions and/or hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, euphoria/elation, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, and appetite and eating change.

26. The pharmaceutical composition of claim 20 or 21, wherein the behavioral and psychological symptom in patient with dementia is agitation/aggression in dementia.

27. The pharmaceutical composition of claim 20 or 21, wherein the behavioral and psychological symptom in patient with dementia is agitation/aggression in Alzheimer's disease dementia.

28. The pharmaceutical composition of claim 26 or 27, wherein the patient has a baseline score of 1 or greater in the agitation/aggression subscale of the NPI-12.

29. The pharmaceutical composition of claim 20 or 21, wherein the behavioral and psychological symptom in patient with dementia is delusions and/or hallucinations in dementia.

30. The pharmaceutical composition of claim 20 or 21, wherein the behavioral and psychological symptom in patient with dementia is delusions and/or hallucinations in Alzheimer's disease dementia.

31. The pharmaceutical composition of claim 29 or 30, wherein the patient has a baseline score of 1 or greater in the delusions and/or hallucinations subscale of the NPI-12.

32. The pharmaceutical composition of claim 29 to 31, wherein the cognitive deficit is treated in patients with delusions and/or hallucinations.

33. The method of claim 8 or the pharmaceutical composition of claim 20 or 21, wherein the pharmaceutically acceptable salt of masupirdine is dimesylate monohydrate.

34. The method of claim 8 or the pharmaceutical composition of claim 21, wherein the pharmaceutically acceptable salt of donepezil is hydrochloride.

35. The method of claim 8 or the pharmaceutical composition of claim 21, wherein the pharmaceutically acceptable salt of memantine is hydrochloride.